Author: ["Hirofumi Noguchi","Masayuki Matsushita","Teru Okitsu","Akiyoshi Moriwaki","Kazuhito Tomizawa","Sunghyun Kang","Sheng-Tian Li","Naoya Kobayashi","Shinichi Matsumoto","Koich Tanaka","Noriaki Tanaka","Hideki Matsui"]
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Calcineurin inhibitors such as cyclosporine A and FK506 have been used for transplant therapy and treatment of autoimmune diseases. However, the inhibition of calcineurin outside the immune system has a number of side effects, including hyperglycemia. In the search for safer drugs, we developed a cell-permeable inhibitor of NFAT (nuclear factor of activated T cells) using the polyarginine peptide delivery system1,2. This peptide provided immunosuppression for fully mismatched islet allografts in mice. In addition, it did not affect insulin secretion, whereas FK506 caused a dose-dependent decrease in insulin secretion. Cell-permeable peptides can thus provide a new strategy for drug development and may eventually be useful clinically.Cite this article
Noguchi, H., Matsushita, M., Okitsu, T. et al. A new cell-permeable peptide allows successful allogeneic islet transplantation in mice. Nat Med 10, 305–309 (2004). https://doi.org/10.1038/nm994 